Adverse perinatal outcomes associated with prenatal exposure to protease-inhibitor-based versus non-nucleoside reverse transcriptase inhibitor-based antiretroviral combinations in pregnant women with HIV infection: a systematic review and meta-analysis

Wedi COO(2016)Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis Lancet HIV 3 e33-48

Kirtley S(2019)Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana N Engl J Med 381 827-840

Hopewell S(2019)Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects J Int AIDS Soc 22 e25352-6

Corrigan R(2007)for the Pediatric Spectrum of HIV Disease Consortium. Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989–2004 PEDIATRICS 119 e900-78

Kennedy SH(2011)Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers JAMA 306 70-1360

Hemelaar J(2012)Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis Off Publ Infect Dis Soc Am 54 1348-95

Zash R(2020)Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002–2014 HIV Med 21 84-1656

Holmes L(2022)Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis EClinicalMedicine 46 101368-621

Diseko M(2020)Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis AIDS Lond Engl 34 1643-83

Jacobson DL(2016)Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland BMC Infect Dis 16 65-854

Wedi COO(2016)Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis Lancet HIV 3 e33-48

Kirtley S(2019)Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana N Engl J Med 381 827-840

Hopewell S(2019)Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects J Int AIDS Soc 22 e25352-6

Corrigan R(2007)for the Pediatric Spectrum of HIV Disease Consortium. Declines in Low Birth Weight and Preterm Birth Among Infants Who Were Born to HIV-Infected Women During an Era of Increased Use of Maternal Antiretroviral Drugs: Pediatric Spectrum of HIV Disease, 1989–2004 PEDIATRICS 119 e900-78

Kennedy SH(2011)Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers JAMA 306 70-1360

Hemelaar J(2012)Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis Off Publ Infect Dis Soc Am 54 1348-95

Zash R(2020)Risk factors during pregnancy and birth-related complications in HIV-positive versus HIV-negative women in Denmark, 2002–2014 HIV Med 21 84-1656

Holmes L(2022)Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis EClinicalMedicine 46 101368-621

Diseko M(2020)Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis AIDS Lond Engl 34 1643-83

Jacobson DL(2016)Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland BMC Infect Dis 16 65-854